Abstract
Premature ejaculation is one of the most prevalent sexual disorders affecting men today. The lack of approved therapies has resulted in the prescription of many ‘off-label’ treatments to manage the condition. Selective serotonin reuptake inhibitors have an interesting side effect of prolonging ejaculatory latency. Consequently, these agents are often considered a first line treatment for patients suffering from premature ejaculation. Erectile dysfunction is another common side effect reported by men treated with selective serotonin reuptake inhibitors. Nitric oxide is the primary mediator of erectile function. Preclinical studies have provided evidence that selective serotonin reuptake inhibitors decrease nitric oxide bioavailability. This invited mini-review aims to examine the physiology of the erectile and ejaculatory responses, discuss the indicated and ‘off-label’ clinical utility of selective serotonin reuptake inhibitors, and to summarize evidence from basic science and clinical studies pertaining to mechanisms of how selective serotonin reuptake inhibitor therapy modifies ejaculatory and erectile function.
Keywords: Erectile dysfunction, PE treatment, premature ejaculation, selective serotonin reuptake inhibitor, SSRI.
Current Drug Safety
Title:Selective Serotonin Reuptake Inhibitors for Premature Ejaculation: Review of Erectile and Ejaculatory Side Effects
Volume: 9 Issue: 2
Author(s): George F. Lasker, Fikret Halis and Ahmet Gokce
Affiliation:
Keywords: Erectile dysfunction, PE treatment, premature ejaculation, selective serotonin reuptake inhibitor, SSRI.
Abstract: Premature ejaculation is one of the most prevalent sexual disorders affecting men today. The lack of approved therapies has resulted in the prescription of many ‘off-label’ treatments to manage the condition. Selective serotonin reuptake inhibitors have an interesting side effect of prolonging ejaculatory latency. Consequently, these agents are often considered a first line treatment for patients suffering from premature ejaculation. Erectile dysfunction is another common side effect reported by men treated with selective serotonin reuptake inhibitors. Nitric oxide is the primary mediator of erectile function. Preclinical studies have provided evidence that selective serotonin reuptake inhibitors decrease nitric oxide bioavailability. This invited mini-review aims to examine the physiology of the erectile and ejaculatory responses, discuss the indicated and ‘off-label’ clinical utility of selective serotonin reuptake inhibitors, and to summarize evidence from basic science and clinical studies pertaining to mechanisms of how selective serotonin reuptake inhibitor therapy modifies ejaculatory and erectile function.
Export Options
About this article
Cite this article as:
Lasker F. George, Halis Fikret and Gokce Ahmet, Selective Serotonin Reuptake Inhibitors for Premature Ejaculation: Review of Erectile and Ejaculatory Side Effects, Current Drug Safety 2014; 9 (2) . https://dx.doi.org/10.2174/1574886309666140120095846
DOI https://dx.doi.org/10.2174/1574886309666140120095846 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD
Current Cardiology Reviews Adherence to Cardiac Practice Guidelines in the Management of Non-ST-Elevation Acute Coronary Syndromes: A Systematic Literature Review
Current Cardiology Reviews A Direct Interaction Between Mitochondrial Proteins and Amyloid-β Peptide and its Significance for the Progression and Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries
Current Pharmacogenomics and Personalized Medicine Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design The Potential Application of Biomaterials in Cardiac Stem Cell Therapy
Current Medicinal Chemistry Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design Molecular Imaging to Monitor Repair of Myocardial Infarction Using Genetically Engineered Bone Marrow-Derived Mesenchymal Stem Cells
Current Gene Therapy Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials
Reviews on Recent Clinical Trials Hematoma Expansion: Clinical and Molecular Predictors and Corresponding Pharmacological Treatment
Current Drug Targets Balancing Antioxidant, Hypolipidemic and Anti-inflammatory Activity in a Single Agent: The Example of 2-Hydroxy-2-Substituted Morpholine, 1,4-Benzoxazine and 1,4-Benzothiazine Derivatives as a Rational Therapeutic Approach against Atherosclerosis
Current Medicinal Chemistry Current Biology of MTP: Implications for Selective Inhibition
Current Topics in Medicinal Chemistry The Role of Drug Transporters in the Pharmacokinetics of Antibiotics
Current Drug Metabolism Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?
Current Pharmaceutical Design Clinical Applicability of Conditioning Techniques in Ischemia-Reperfusion Injury: A Review of the Literature
Current Cardiology Reviews PPARγ Activation Improves the Molecular and Functional Components of Ito Remodeling by Angiotensin II
Current Pharmaceutical Design Prevalence of Obesity, Hypertension, Diabetes, and Metabolic Syndrome and Its Cardiovascular Complications
Current Hypertension Reviews Integrin Signaling Networks in the Pathobiology of Vascular Smooth Muscle Cells
Vascular Disease Prevention (Discontinued) The Impact of CRISPR/Cas9-Based Genomic Engineering on Biomedical Research and Medicine
Current Molecular Medicine